Circulating tumor DNA

News and Video Search Results

News coverage

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

GlobeNewswire 16 May 2024

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free..

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
GlobeNewswire 15 May 2024
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
GlobeNewswire 15 May 2024
U.S. Liquid Biopsy Market to Attain Valuation of USD 12,004.9 Million By 2032: Astute Analytica
GlobeNewswire 08 May 2024
[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
GlobeNewswire 06 May 2024

0 shares 1 views

You might like

Circulating tumor DNA media coverage

BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 06 May 2024

· Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase..

Advertisement

More coverage

Nvidia & darpa biohybrid

Nvidia & darpa biohybrid

Rumble 29 Mar 2024

https://www.youtube.com/watch?v=0Hg7XhbXuac . No One is Talking About What Just Happened..